Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation

PLoS Genetics

Volumn 10, Issue 9, 2014, Pages

  Popovic, Relja ^a   Martinez Garcia, Eva ^a   Giannopoulou, Eugenia G ^b,c   Zhang, Quanwei ^d   Zhang, Qingyang ^d   Ezponda, Teresa ^a   Shah, Mrinal Y ^a   Zheng, Yupeng ^d   Will, Christine M ^a   Small, Eliza C ^a   Hua, Youjia ^a   Bulic, Marinka ^a   Jiang, Yanwen ^e   Carrara, Matteo ^f   Calogero, Raffaele A ^f   Kath, William L ^g   Kelleher, Neil L ^d   Wang, Ji Ping ^d   Elemento, Olivier ^e   Licht, Jonathan D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c NEW YORK CITY COLLEGE OF TECHNOLOGY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF TURIN   (Italy)

^g Northwestern University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; HISTONE H3; HISTONE METHYLTRANSFERASE; MMSET PROTEIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; CHROMATIN; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; LYSINE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATIN; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENE REPRESSION; HISTONE METHYLATION; MOUSE; MYELOMA; MYELOMA CELL; NOD SCID MOUSE; NONHUMAN; PHD DOMAIN; PROTEIN DOMAIN; PWWP DOMAIN; SURVIVAL TIME; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; CELL LINE; CELL TRANSFORMATION; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MULTIPLE MYELOMA;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LYSINE; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; RNA, SMALL INTERFERING;

EID: 84907572364     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004566     Document Type: Article

References (74)

1. Popovic R, Licht JD, (2012) Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2: 405–413.
2. Morey L, Helin K, (2010) Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 35: 323–332.
3. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871–874.
4. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, et al. (2006) Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441: 349–353.
5. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, et al. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42: 181–185.
6. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, et al. (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23: 677–692.
7. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, et al. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22: 180–193.
8. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722–726.
9. Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, et al. (2012) Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 119: 1208–1213.
10. Li Y, Trojer P, Xu CF, Cheung P, Kuo A, et al. (2009) The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. J Biol Chem 284: 34283–34295.
11. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, et al. (2011) NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 44: 609–620.
12. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, et al. (2011) The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117: 211–220.
13. Wagner EJ, Carpenter PB, (2012) Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol 13: 115–126.
14. Bergemann AD, Cole F, Hirschhorn K, (2005) The etiology of Wolf-Hirschhorn syndrome. Trends Genet 21: 188–195.
15. Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, et al. (2009) A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 460: 287–291.
16. Keats JJ, Reiman T, Belch AR, Pilarski LM, (2006) Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 47: 2289–2300.
17. Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, et al. (1998) WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 7: 1071–1082.
18. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, et al. (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101: 1520–1529.
19. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J, Jr (2003) A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101: 2374–2376.
20. Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, et al. (2012) The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 32 (23) 2882–90.
21. Hudlebusch HR, Santoni-Rugiu E, Simon R, Ralfkiaer E, Rossing HH, et al. (2011) The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res 17: 2919–2933.
22. Zhou P, Wu LL, Wu KM, Jiang W, Li JD, et al. (2013) Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma. Pathol Oncol Res 19: 303–309.
23. Yang S, Zhang Y, Meng F, Liu Y, Xia B, et al. (2013) Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma. Biomarkers 18: 257–263.
24. Oyer JA, Huang X, Zheng Y, Shim J, Ezponda T, et al. (2013) Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia 28 (1) 198–201.
25. Jaffe JD, Wang Y, Chan HM, Zhang J, Huether R, et al. (2013) Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet 45: 1386–1391.
26. Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, et al. (2008) The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 111: 856–864.
27. Zheng Y, Sweet SM, Popovic R, Martinez-Garcia E, Tipton JD, et al. (2012) Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proc Natl Acad Sci U S A 109: 13549–13554.
28. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, et al. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57–74.
29. Huang N, Kawano MM, Mahmoud MS, Mihara K, Tsujimoto T, et al. (1995) Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells. Blood 85: 3704–3712.
30. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-resolution profiling of histone methylations in the human genome. Cell 129: 823–837.
31. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, et al. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40: 741–750.
32. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K, (2006) Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 20: 1123–1136.
33. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
34. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, et al. (2006) The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 107: 2170–2179.
35. Schmitges FW, Prusty AB, Faty M, Stutzer A, Lingaraju GM, et al. (2011) Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell 42: 330–341.
36. Yuan W, Xu M, Huang C, Liu N, Chen S, et al. (2011) H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem 286: 7983–7989.
37. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, et al. (2006) A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210: 67–85.
38. Granit RZ, Gabai Y, Hadar T, Karamansha Y, Liberman L, et al. (2012) EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene 32 (33) 3886–95.
39. Mendenhall EM, Koche RP, Truong T, Zhou VW, Issac B, et al. (2010) GC-rich sequence elements recruit PRC2 in mammalian ES cells. PLoS Genet 6: e1001244.
40. Verma SK, LaFrance LV, Suarez DP, et al. (2012) Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Medical Chemistry Letters 3: 1091–1096.
41. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, et al. (2000) Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 97: 228–233.
42. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, et al. (2011) Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25: 1026–1035.
43. Min DJ, Ezponda T, Kim MK, Will CM, Martinez-Garcia E, et al. (2013) MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC. Leukemia 27: 686–694.
44. Baker LA, Allis CD, Wang GG, (2008) PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. Mutat Res 647: 3–12.
45. Wu H, Zeng H, Lam R, Tempel W, Amaya MF, et al. (2011) Structural and histone binding ability characterizations of human PWWP domains. PLoS One 6: e18919.
46. Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, et al. (2002) Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30: 365–366.
47. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, et al. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: 1058–1066.
48. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, et al. (2009) Mutation in TET2 in myeloid cancers. N Engl J Med 360: 2289–2301.
49. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360–363.
50. Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, et al. (2010) Polycomb target genes are silenced in multiple myeloma. PLoS One 5: e11483.
51. Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, et al. (2007) Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11: 513–525.
52. Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, et al. (2009) Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139: 1290–1302.
53. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, et al. (2009) Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461: 762–767.
54. Van Bortle K, Ramos E, Takenaka N, Yang J, Wahi JE, et al. (2012) Drosophila CTCF tandemly aligns with other insulator proteins at the borders of H3K27me3 domains. Genome Res 22: 2176–2187.
55. Lhoumaud P, Hennion M, Gamot A, Cuddapah S, Queille S, et al. (2014) Insulators recruit histone methyltransferase dMes4 to regulate chromatin of flanking genes. EMBO J 33 (14) 1599–613.
56. Gaydos LJ, Rechtsteiner A, Egelhofer TA, Carroll CR, Strome S, (2012) Antagonism between MES-4 and Polycomb Repressive Complex 2 Promotes Appropriate Gene Expression in C. elegans Germ Cells. Cell Rep 2 (5) 1169–77.
57. Blackledge NP, Zhou JC, Tolstorukov MY, Farcas AM, Park PJ, et al. (2010) CpG islands recruit a histone H3 lysine 36 demethylase. Mol Cell 38: 179–190.
58. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482: 226–231.
59. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, et al. (2013) Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell 49: 80–93.
60. He C, Li F, Zhang J, Wu J, Shi Y, (2013) The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. J Biol Chem 288: 4692–4703.
61. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, et al. (2011) NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 118: 3645–3656.
62. Wang GG, Cai L, Pasillas MP, Kamps MP, (2007) NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 9: 804–812.
63. Faravelli F, (2005) NSD1 mutations in Sotos syndrome. Am J Med Genet C Semin Med Genet 137C: 24–31.
64. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, et al. (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481: 157–163.
65. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, et al. (2009) Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 41: 521–523.
66. Croonquist PA, Van Ness B, (2005) The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24: 6269–6280.
67. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904–917.
68. Creasy CL, McCabe MT, Korenchuk S, Diaz E, Ott H, et al. (2012) A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutations. Chicago: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. pp. 492.
69. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, et al. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492 (7427) 108–12.
70. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137.
71. Giannopoulou EG, Elemento O, (2011) An integrated ChIP-seq analysis platform with customizable workflows. BMC Bioinformatics 12: 277.
72. Elemento O, Slonim N, Tavazoie S, (2007) A universal framework for regulatory element discovery across all genomes and data types. Mol Cell 28: 337–350.
73. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, et al. (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38: 576–589.
74. Goodarzi H, Elemento O, Tavazoie S, (2009) Revealing global regulatory perturbations across human cancers. Mol Cell 36: 900–911.